Navigating product discontinuation has long been a complex and often confusing challenge for pharmaceutical manufacturers. What might seem like a simple step—removing a product from the market—quickly becomes complicated by varying requirements from the FDA, CMS, and major compendia organizations. The result is a fragmented process with unclear guidance, inconsistent timelines, and limited coordination.
That’s why we’re excited to highlight the expertise of Alisha Nielsen, Vice President, SME Compendia & eHRX at Two Labs, an Envision Pharma Company, who contributed valuable insights to a newly released NCPDP whitepaper focused on bringing clarity to this critical issue.
Dates associated with
pharmaceutical products
